AstraZeneca's Rezield Hits Another Regulatory Wall
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues a second "complete response" letter for the respiratory syncytial virus prophylaxis agent, this time seeking a new clinical trial.
You may also be interested in...
AstraZeneca Pulls Motavizumab Prophylaxis BLA, But Phase II Trial Continues
Company takes a $445 million charge after apparently opting not to undertake an additional trial that FDA had requested following an advisory committee, but the firm is still pursuing a possible claim for treatment of respiratory syncytial virus disease.
AstraZeneca Pulls Motavizumab Prophylaxis BLA, But Phase II Trial Continues
Company takes a $445 million charge after apparently opting not to undertake an additional trial that FDA had requested following an advisory committee, but the firm is still pursuing a possible claim for treatment of respiratory syncytial virus disease.
FDA Delays Action On MedImmune's Rezield Despite Negative Panel Vote
Agency may have needed more time to investigate allegations in a wrongful discharge lawsuit challenging data integrity in a motavizumab surveillance study.